Research and Development Investment: Perrigo Company plc vs Evotec SE

R&D Investment Trends: Perrigo vs Evotec (2014-2023)

__timestampEvotec SEPerrigo Company plc
Wednesday, January 1, 201412404000152500000
Thursday, January 1, 201518343000187800000
Friday, January 1, 201618108000184000000
Sunday, January 1, 201717614000167700000
Monday, January 1, 201835619000218600000
Tuesday, January 1, 201958432000187400000
Wednesday, January 1, 202063945000177700000
Friday, January 1, 202172200000122000000
Saturday, January 1, 202276642000123100000
Sunday, January 1, 202357519000122500000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of R&D Investment: Perrigo Company plc vs Evotec SE

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) investment is a critical driver of innovation and growth. Over the past decade, from 2014 to 2023, Perrigo Company plc and Evotec SE have demonstrated contrasting strategies in their R&D expenditures. Perrigo, a global leader in over-the-counter health and wellness solutions, consistently invested significantly more in R&D, with an average annual expenditure of approximately $164 million. In contrast, Evotec SE, a prominent player in drug discovery and development, averaged around $43 million annually.

Interestingly, while Perrigo's R&D spending peaked in 2018, Evotec's investment showed a steady upward trend, reaching its highest in 2022. This divergence highlights Perrigo's focus on maintaining a robust product pipeline, while Evotec's strategy emphasizes gradual, sustainable growth. As the pharmaceutical industry continues to innovate, these investment patterns offer valuable insights into the strategic priorities of these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025